The data displays the market capitalization of public biotech companies from 2012 to 2014, sorted by U.S. region (metropolitan region). In New England, the total market capitalization of all public biotech companies came to approx. 85 billion USD in 2012.
U.S. public biotech companies
The San Francisco Bay Area and New England have some of the most successful public biotechnology companies in the U.S., with each region totaling some 210.8 billion USD and 209.6 billion USD in market capitalization, respectively, as of 2014.
